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Introduction
Restless legs syndrome (RLS) is the most common movement
disorder and is characterized by the feeling of an urgent need to move
the legs while lying down or resting. RLS worsens during the evening
and at night and is relieved by leg movement.1,2 It is also known that
RLS is commonly comorbid with Parkinson’s disease (PD).3 Although
the exact pathological mechanism of RLS is unknown, dopaminergic
medications for PD, such as levodopa and other dopamine agonists,
symptomatically improve RLS as well.4
Istradefylline is a highly selective adenosine A2A receptor antagonist
that is thought to modulate the overactivated striatopallidal pathway
(indirect pathway) in PD,4 reducing the duration of the ‘‘off’’ state and
extending the ‘‘on’’ state without inducing dyskinesia.5 Istradefylline
has been recently approved in Japan for the treatment of PD, but, to
date, there are no data on the effect of istradefylline on RLS in PD.
Here we report the cases of three patients with RLS comorbid with PD
who were treated with istradefylline.
Case reports
Case 1
A 73-year-old right-handed male had developed a tremor in
his right lower limb at the age of 61 years. He began taking selegi-
line 5 mg/day at the age of 62 years but experienced only mild
improvement and subsequently began taking pramipexole 1 mg/day.
As wearing-off developed, and he found it difficult to work when in the
‘‘off’’ state at the age of 70, he began taking istradefylline 20 mg/day,
which improved his gait. After a while, as wearing-off got severe, he
also started to feel discomfort at night. This discomfort led to an urge
to walk around, and the patient experienced relief after walking;
his istradefylline was increased to 40 mg/day for his parkinsonism.
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His parkinsonism improved, and his Unified Parkinson’s Disease
Rating Scale part 3 (UPDRS-III) score improved from 40 to 30. The
increased istradefylline subsequently improved his RLS symptoms, and
resulted in complete remission. The discomfort in his legs that made him
feel the need to move his legs disappeared. His score on the International
RLS Study Group RLS Severity Scale6 improved from 18 to 0 points.
This improvement lasted at least 30 months without augmentation.
Case 2
A 65-year-old right-handed male had developed a resting tremor in
his right hand at the age of 54 years and was subsequently diagnosed
with PD. He began taking pramipexole extended release (2 mg/day),
but development of gait disturbance required an increase in dosage
to 3 mg/day; however, the dosage increase resulted in hypersexuality.
His medication was then changed from pramipexole extended release
to ropinirole controlled release, and he was started on levodopa/
carbidopa (150 mg/day) at the age of 62 years. After a while, he began
to feel the urgency to walk around when he was resting, particularly in
the evening and at night. He was started on istradefylline (20 mg/day),
and his RLS symptoms improved and almost disappeared, and resulted
in an improvement in his sleep. The improvement lasted 5 months
until he stopped taking istradefylline due to the initiation of
levodopa/carbidopa infusion gel therapy because of a wearing-off
and dyskinesia.
Case 3
A 49-year-old right-handed male noted slowness in his left leg and
difficulty in using his left hand at the age of 44 years. He began to take
pramipexole (up to 3.75 mg/day), which effectively improved the PD
symptoms. At the age of 46 years, he was prescribed selegiline 2.5 mg/
day in addition because of wearing-off. His left leg began dragging at
the age of 47 years, and he started falling down occasionally. He also
reported sleep disturbance and an urgency to move his legs at age
49 years. Istradefylline (20 mg/day) was started, and the feelings of
urgently needing to move his legs diminished and his quality of sleep
improved remarkably. This effect lasted at least 17 months.
Discussion
Summaries of the outcomes of the three cases are presented in Table 1.
In all three cases, introducing or increasing istradefylline produced a
favorable response to both RLS and PD symptoms. Patients in all three
cases reported feeling the urgent need to move their legs when resting
or lying in bed. The symptoms worsened in the evening and at night,
leading to sleep disturbance in at least one case. Starting or increasing
istradefylline subjectively improved the RLS symptoms in all three cases.
To the best of our knowledge, this is the first report that notes that
istradefylline improves RLS that is comorbid with PD.
One of the hypothesized mechanisms suggests that istradefylline
improved the ‘‘hidden’’ RLS that became unmasked in the ‘‘off’’ state
of PD. Improving parkinsonism may subsequently improve the under-
lying RLS in PD. In fact, RLS is thought to occur in up to 50% of
patients with PD,3 but the symptoms of RLS may be masked by anti-
PD dopaminergic treatment.7 Undertreatment of PD can unmask
RLS. In addition, there are reports indicating that the motor symp-
toms of PD improved as expected after subthalamic deep brain stimu-
lation but that reducing dopaminergic medication led to unmasking
of RLS.8
It is also possible that istradefylline directly improves RLS. One
suggested pathogenetic mechanism of RLS is brain iron deficiency.1
Current studies have indicated that adenosine receptors play a sig-
nificant role in both brain iron deficiency and sleep disorders in RLS.1
One study demonstrated a significant downregulation of adenosine
A1 receptors and upregulation of adenosine A2A receptors in RLS.1
Thus, inhibiting adenosine A2A receptors may directly improve RLS,
although this hypothesis remains speculative.
A third hypothesis suggests that the improvement in dopamine
agonist-induced daytime somnolence upon administration of istrade-
fylline could improve RLS at night. Istradefylline is an analog of the
stimulant caffeine, and it is known to be anti-somnogenic.4 However,
the extent of these potential interactions is still unknown.
In conclusion, istradefylline may be efficacious against RLS that is
comorbid with PD. Further prospective studies are needed to confirm
our observations.
Table 1. Patient Characteristics of the Three Presented Cases
Case 1 Case 2 Case 3
Age/sex 73/M 65/M 52/M
Parkinson’s disease duration (years) 12 11 5
Dosage of istradefylline 20 mg 40 mg 20 mg
L-dopa + + +
Dopamine agonist + + +
Follow-up 30 months 5 months 17 months
Augmentation – – –
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